Ascent Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ascent Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$495K	Buy	4,937 +1	+0%	+$90	0.39%	33
2025 Q2	$409K	Buy	4,936 +1	+0%	+$80	0.36%	36
2025 Q1	$400K	Hold	4,935	–	–	0.4%	36
2024 Q4	$444K	Buy	+4,935	New	+$478K	0.45%	32

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ascent Capital Management's XBI Position: Q3 2025 in Review

Ascent Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.02% in Q3 2025, buying an estimated $90 and bringing the position to 4,937 shares worth $495K. The position accounts for 0.39% of the portfolio, ranked #33.

Ascent Capital Management first reported a position in XBI in Q4 2024 and has held it in 4 quarters since. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Ascent Capital Management held 4,937 shares of State Street SPDR S&P Biotech ETF worth $495K as of Q3 2025.
Ascent Capital Management bought 1 State Street SPDR S&P Biotech ETF share in Q3 2025, an estimated $90.
State Street SPDR S&P Biotech ETF made up 0.39% of Ascent Capital Management's portfolio in Q3 2025, its #33 holding.
Ascent Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 4 quarters since.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Ascent Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.